In vitro inhibition of Plasmodium falciparum Rosette formation by curdlan sulfate
In vitro inhibition of Plasmodium falciparum Rosette formation by curdlan sulfate
复制标题
DOI：
10.1128/aac.01216-06
复制
发表时间：
2007-04-01
影响因子：
4.9
通讯作者：
Rowe, J. Alexandra
中科院分区：
文献类型：
--
作者：
Kyriacou, Helen M.;Steen, Katie E.;Rowe, J. Alexandra
感染的红细胞与未感染的红细胞自发结合形成玫瑰花环是某些恶性疟原虫株的特性，与疟疾的严重并发症有关。柯德兰硫酸盐(CRDS)是一种硫酸化的糖共轭化合物，其化学结构类似于已知的玫瑰花结抑制药物，如肝素。此前，CRDS已被证明具有体外抗疟疾活性，临床使用是安全的。在这里，我们显示了治疗水平(10到100微克/毫升)的CRDS显著减少了7个恶性疟原虫实验室菌株和18个非洲临床分离株在硝基体内形成的玫瑰花环。强大的抑制玫瑰花结的能力表明，CRDS有可能降低非洲儿童恶性疟原虫疟疾的严重并发症和死亡率。我们的数据支持CRDS的进一步临床试验。
Spontaneous binding of infected erythrocytes to uninfected erythrocytes to form rosettes is a property of some strains of Plasmodium falciparum that is linked to severe complications of malaria. Curdlan sulfate (CRDS) is a sulfated glycoconjugate compound that is chemically similar to known rosette-inhibiting drugs such as heparin. CRDS has previously been shown to have antimalarial activity in vitro and is safe for clinical use. Here we show that CRDS at therapeutic levels (10 to 100 mu g/ml) significantly reduces rosette formation in Nitro in seven P. falciparum laboratory strains and in a group of 18 African clinical isolates. The strong ability to inhibit rosetting suggests that CRDS has the potential to reduce the severe complications and mortality rates from P. falciparum malaria among African children. Our data support further clinical trials of CRDS.